|Bid||111.83 x 800|
|Ask||114.39 x 1100|
|Day's Range||114.01 - 115.89|
|52 Week Range||78.90 - 116.47|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||39.89|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||0.66 (0.57%)|
|1y Target Est||118.50|
Spencer recently disclosed other transactions, including selling Zoetis stock and buying Verra Mobility shares.
Since Zoetis Inc. (NYSE:ZTS) released its earnings in March 2019, analyst forecasts seem fairly subdued, with earnings...
Pfizer stock has run sideways this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
Investors love the companies that keep pets healthy. Now a merger between two of the five largest players could mean more gains for shareholders.
The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Recession-proof industries are unique. They sell stuff that people buy no matter what’s happening in the economy — things like electricity, internet access, toilet paper. And now pet care. That’s right: America is pet obsessed.
Read the beginning of this article here. At the end of March 2019, Marshall Wace held the most valuable position in Zoetis Inc. (NYSE:ZTS), the biggest producer of vaccinations and medicine for livestock and pets that was once a part of the world’s biggest drug maker, Pfizer. The company has a market cap of $54.81 […]
Zoetis Inc’s (NYSE: ZTS ) stock has appreciated significantly year-to-date on a continued “safety haven” trade and upside to 2020 results on the basis of the upcoming launch of Simparica Trio, according ...
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Tuesday, Aug. 6, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2019 financial results and respond to questions from financial analysts during the call.
I don't think we are on the verge of a bear market in stocks. However, there are many warning signs that suggest that an economic downturn and a bear market are on the horizon, notes Jim Powell, a growth and income expert, and the editor of Global Changes & Opportunities Report.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Zoetis Inc NYSE:ZTSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ZTS totaled $5.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In this daily bar chart of ZTS, below, we can see that prices just broke out on the upside. ZTS is above the rising 50-day moving average line after a number of tests of the line since the middle of April. The volume of trading doesn't seem to show much but the On-Balance-Volume (OBV) line rose with the price action from late January.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Wendys Co (NASDAQ: WEN ) is one of his absolute favorites. Cramer is a buyer of Zoetis Inc (NYSE: ZTS ). He added that the stock hit another ...
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Driven by ESG investing and built to thrive in a market correction, Calvert Equity is among the best mutual funds this year, topping the S&P by 50%.
Pharmaceuticals are a tricky business. Public policy, science, R&D;, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.But some Big Pharma companies and a few other industry firms have managed these and other factors better than others. And along the way, they have built up a considerable "moat" - some sort of considerable competitive advantage - around profitable businesses. Some of these same companies are building bridges to further profitability via deep drug pipelines, innovative new treatments and transformative acquisitions.Here's a deeper look into five pharmaceutical stocks that have compelling moats, bridges or both. These advantages make them more likely to provide stable growth over the long term. SEE ALSO: The Best Health-Care Stocks to Buy for 2019